What is your approach to the decision to use CPX-351 or standard 7+3 for de novo AML?

Do you await molecular and cytogenetic results prior to initiating therapy, or does age and function status primarily drive your choice?

2 Answers

Mednet MemberInvited Expert

Medical Oncology · Columbia University Medical Center

Answered on

CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. It was approved by the FDA in 2017 for the treatment of adults with newly-diagnosed therapy-related acute my...

Join for free or sign in to see the full answer

Mednet Member

Medical Oncology · Novant Cancer Institute

Answered on

We typically temporize with supportive care/hydrea and get the relevant data back within a week.

Join for free or sign in to see the full answer